Carrier-Mediated Drug Uptake in Fungal Pathogens
Abstract
:1. Introduction
2. Drugs Imported by Known Transporter(s) in Pathogenic Fungi
3. Drugs Imported by Known Transporter(s) in the Model Yeast Saccharomyces cerevisiae or in Human Parasites—Their Homologs in Pathogenic Fungi
3.1. Clues from the Model Yeast Saccharomyces cerevisiae
3.2. Clues from Human Protozoa Pathogens
3.2.1. Leishmania
3.2.2. Trypanosoma
4. Conclusions and Perspectives
Author Contributions
Funding
Conflicts of Interest
References
- Liu, X. Transporter-mediated drug-drug interactions and their significance. In Advances in Experimental Medicine and Biology; Springer: New York, NY, USA, 2019; Volume 1141, pp. 241–291. [Google Scholar]
- Sai, Y.; Tsuji, A. Transporter-mediated drug delivery: Recent progress and experimental approaches. Drug Discov. Today 2004, 9, 712–720. [Google Scholar] [CrossRef]
- Sai, Y. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. Drug Metab. Pharmacokinet. 2005, 20, 91–99. [Google Scholar] [CrossRef] [Green Version]
- Cunha, E.; Rocha, K.; Pereira, B.M.V.; Rodrigues, A.C. An update on efflux and uptake transporters as determinants of statin response. Expert Opin. Drug Metab. Toxicol. 2018, 14, 613–624. [Google Scholar]
- Lanthaler, K.; Bilsland, E.; Dobson, P.D.; Moss, H.J.; Pir, P.; Kell, D.B.; Oliver, S.G. Genome-wide assessment of the carriers involved in the cellular uptake of drugs: A model system in yeast. BMC Biol. 2011, 9, 70. [Google Scholar] [CrossRef] [Green Version]
- Xie, J.L.; Polvi, E.J.; Shekhar-Guturja, T.; Cowen, L.E. Elucidating drug resistance in human fungal pathogens. Future Microbiol. 2014, 9, 523–542. [Google Scholar] [CrossRef] [PubMed]
- Capela, R.; Moreira, R.; Lopes, F. An overview of drug resistance in protozoal diseases. Int. J. Mol. Sci. 2019, 20, 5748. [Google Scholar] [CrossRef] [Green Version]
- Perlin, M.H.; Andrews, J.; Toh, S.S. Essential letters in the fungal alphabet: ABC and MFS transporters and their roles in survival and pathogenicity. Adv. Genet. 2014, 85, 201–2053. [Google Scholar]
- Alibert-Franco, S.; Pradines, B.; Mahamoud, A.; Davin-Regli, A.; Pages, J.-M. Efflux Mechanism, an Attractive Target to Combat Multidrug Resistant Plasmodium falciparum and Pseudomonas aeruginosa. Curr. Med. Chem. 2008, 16, 301–317. [Google Scholar] [CrossRef]
- Houšť, J.; Spížek, J.; Havlíček, V. Antifungal Drugs. Metabolites 2020, 10, 106. [Google Scholar] [CrossRef] [Green Version]
- Campos, M.C.O.; Castro-Pinto, D.B.; Ribeiro, G.A.; Berredo-Pinho, M.M.; Gomes, L.H.F.; Da Silva Bellieny, M.S.; Goulart, C.M.; Echevarria, Á.; Leon, L.L. P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance. Parasitol. Res. 2013, 112, 2341–2351. [Google Scholar] [CrossRef] [Green Version]
- Dobson, P.; Lanthaler, K.; Oliver, S.; Kell, D. Implications of the Dominant Role of Transporters in Drug Uptake by Cells. Curr. Top. Med. Chem. 2009, 9, 163–181. [Google Scholar] [CrossRef] [Green Version]
- Kell, D.B.; Oliver, S.G.; De Koning, H.P. How drugs get into cells: Tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front. Pharmacol. 2014, 5, 1–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mukhopadhyay, K.; Kohli, A.; Prasad, R. Drug susceptibilities of yeast cells are affected by membrane lipid composition. Antimicrob. Agents Chemother. 2002, 46, 3695–3705. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prasad, T.; Chandra, A.; Mukhopadhyay, C.K.; Prasad, R. Unexpected link between iron and drug resistance of Candida spp.: Iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells. Antimicrob. Agents Chemother. 2006, 50, 3597–3606. [Google Scholar] [CrossRef] [Green Version]
- Mansfield, B.E.; Oltean, H.N.; Oliver, B.G.; Hoot, S.J.; Leyde, S.E.; Hedstrom, L.; White, T.C. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog. 2010, 6, 1–11. [Google Scholar] [CrossRef] [Green Version]
- Esquivel, B.D.; Smith, A.R.; Zavrel, M.; White, T.C. Azole drug import into the pathogenic fungus Aspergillus fumigatus. Antimicrob. Agents Chemother. 2015, 59, 3390–3398. [Google Scholar] [CrossRef] [Green Version]
- Liu, Z.; Boles, E.; Rosen, B.P. Arsenic Trioxide Uptake by Hexose Permeases in Saccharomyces cerevisiae. J. Biol. Chem. 2004, 279, 17312–17318. [Google Scholar] [CrossRef] [Green Version]
- Jochem, M.; Ende, L.; Isasa, M.; Ang, J.; Schnell, H.; Guerra-Moreno, A.; Micoogullari, Y.; Bhanu, M.; Gygi, S.P.; Hanna, J. Targeted Degradation of Glucose Transporters Protects against Arsenic Toxicity. Mol. Cell. Biol. 2019, 39, 1–15. [Google Scholar] [CrossRef] [Green Version]
- Hasne, M.P.; Barrett, M.P. Drug uptake via nutrient transporters in Trypanosoma brucei. J. Appl. Microbiol. 2000, 89, 697–701. [Google Scholar] [CrossRef]
- Vandeputte, P.; Pineau, L.; Larcher, G.; Noel, T.; Brèthes, D.; Chabasse, D.; Bouchara, J.-P. Molecular Mechanisms of Resistance to 5-Fluorocytosine in Laboratory Mutants of Candida glabrata. Mycopathologia 2011, 171, 11–21. [Google Scholar] [CrossRef] [Green Version]
- Hope, W.W.; Tabernero, L.; Denning, D.W.; Anderson, M.J. Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans. Antimicrob. Agents Chemother. 2004, 48, 4377–4386. [Google Scholar] [CrossRef] [Green Version]
- Gsaller, F.; Furukawa, T.; Carr, P.D.; Rash, B.; Jöchl, C.; Bertuzzi, M.; Bignell, E.M.; Bromley, M.J. Mechanistic basis of pH-dependent 5-flucytosine resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 2018, 62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Claus, S.; Jezierska, S.; Van Bogaert, I.N.A. Protein-facilitated transport of hydrophobic molecules across the yeast plasma membrane. FEBS Lett. 2019, 593, 1508–1527. [Google Scholar] [CrossRef] [Green Version]
- Ben-Ami, R.; Zimmerman, O.; Finn, T.; Amit, S.; Novikov, A.; Wertheimer, N.; Lurie-Weinberger, M.; Berman, J. Heteroresistance to fluconazole is a continuously distributed phenotype among Candida glabrata clinical strains associated with in vivo persistence. MBio 2016, 7. [Google Scholar] [CrossRef] [Green Version]
- Resendiz Sharpe, A.; Lagrou, K.; Meis, J.F.; Chowdhary, A.; Lockhart, S.R.; Verweij, P.E. Triazole resistance surveillance in Aspergillus fumigatus. Med. Mycol. 2018, 56, S83–S92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gabriel, F.; Sabra, A.; El-Kirat-chatel, S.; Pujol, S.; Fitton-Ouhabi, V.; Brèthes, D.; Dementhon, K.; Accoceberry, I.; Noël, T. Deletion of the uracil permease gene confers cross-resistance to 5-fluorouracil and azoles in Candida lusitaniae and highlights antagonistic interaction between fluorinated nucleotides and fluconazole. Antimicrob. Agents Chemother. 2014, 58, 4476–4485. [Google Scholar] [CrossRef] [Green Version]
- Chen, Y.N.; Lo, H.J.; Wu, C.C.; Ko, H.C.; Chang, T.P.; Yang, Y.L. Loss of heterozygosity of FCY2 leading to the development of flucytosine resistance in Candida tropicalis. Antimicrob. Agents Chemother. 2011, 55, 2506–2514. [Google Scholar] [CrossRef] [Green Version]
- Xu, D.; Jiang, B.; Ketela, T.; Lemieux, S.; Veillette, K.; Martel, N.; Davison, J.; Sillaots, S.; Trosok, S.; Bachewich, C.; et al. Genome-Wide Fitness Test and Mechanism-of-Action Studies of Inhibitory Compounds in Candida albicans. PLoS Pathog. 2007, 3, e92. [Google Scholar] [CrossRef] [Green Version]
- Paluszynski, J.P.; Klassen, R.; Rohe, M.; Meinhardt, F. Various cytosine/adenine permease homologues are involved in the toxicity of 5-flourocytosine in Saccharomyces cerevisiae. Yeast 2006, 23, 707–715. [Google Scholar] [CrossRef] [Green Version]
- Florent, M.; Noël, T.; Ruprich-Robert, G.; Da Silva, B.; Fitton-Ouhabi, V.; Chastin, C.; Papon, N.; Chapeland-Leclerc, F. Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae. Antimicrob. Agents Chemother. 2009, 53, 2982–2990. [Google Scholar] [CrossRef] [Green Version]
- Papon, N.; Noël, T.; Florent, M.; Gibot-Leclerc, S.; Jean, D.; Chastin, C.; Villard, J.; Chapeland-Leclerc, F. Molecular mechanism of flucytosine resistance in Candida lusitaniae: Contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrob. Agents Chemother. 2007, 51, 369–371. [Google Scholar] [CrossRef] [Green Version]
- Vu, K.; Thompson, G.R.; Roe, C.C.; Sykes, J.E.; Dreibe, E.M.; Lockhart, S.R.; Meyer, W.; Engelthaler, D.M.; Gelli, A. Flucytosine resistance in Cryptococcus gattii is indirectly mediated by the FCY2-FCY1-FUR1 pathway. Med. Mycol. 2018, 56, 857–867. [Google Scholar] [CrossRef]
- Whelan, W.L. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit. Rev. Microbiol. 1987, 15, 45–56. [Google Scholar] [CrossRef] [PubMed]
- Vlanti, A.; Diallinas, G. The Aspergillus nidulans FcyB cytosine-purine scavenger is highly expressed during germination and in reproductive compartments and is downregulated by endocytosis. Mol. Microbiol. 2008, 68, 959–977. [Google Scholar] [CrossRef]
- Nakamura, I.; Ohsumi, K.; Takeda, S.; Katsumata, K.; Matsumoto, S.; Akamatsu, S.; Mitori, H.; Nakai, T. ASp2397 is a novel natural compound that exhibits rapid and potent fungicidal activity against Aspergillus species through a specific transporter. Antimicrob. Agents Chemother. 2019, 63, 1–13. [Google Scholar] [CrossRef]
- Dietl, A.M.; Misslinger, M.; Aguiar, M.M.; Ivashov, V.; Teis, D.; Pfister, J.; Decristoforo, C.; Hermann, M.; Sullivan, S.M.; Smith, L.R.; et al. The siderophore transporter Sit1 determines susceptibility to the antifungal VL-2397. Antimicrob. Agents Chemother. 2019, 63, e00807-19. [Google Scholar] [CrossRef]
- Sun, N.; Li, D.; Fonzi, W.; Li, X.; Zhang, L.; Calderone, R. Multidrug-resistant transporter Mdr1p-mediated uptake of a novel antifungal compound. Antimicrob. Agents Chemother. 2013, 57, 5931–5939. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Monteiro, P.T.; Oliveira, J.; Pais, P.; Antunes, M.; Palma, M.; Cavalheiro, M.; Galocha, M.; Godinho, C.P.; Martins, L.C.; Bourbon, N.; et al. YEASTRACT+: A portal for cross-species comparative genomics of transcription regulation in yeasts. Nucleic Acids Res. 2020, 48, D642–D649. [Google Scholar] [CrossRef]
- Altschul, S.F.; Gish, W.; Miller, W.; Myers, E.W.; Lipman, D.J. Basic local alignment search tool. J. Mol. Biol. 1990, 215, 403–410. [Google Scholar] [CrossRef]
- Benson, D.A.; Cavanaugh, M.; Clark, K.; Karsch-Mizrachi, I.; Lipman, D.J.; Ostell, J.; Sayers, E.W. GenBank. Nucleic Acids Res. 2013, 41, 1195. [Google Scholar] [CrossRef] [Green Version]
- The Rapid Generation of Mutation Data Matrices from Protein Sequences—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/1633570/ (accessed on 30 July 2020).
- MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/29722887/ (accessed on 30 July 2020).
- Hibbett, D.S.; Blackwell, M.; James, T.Y.; Spatafora, J.W.; Taylor, J.W.; Vilgalys, R. Phylogenetic taxon definitions for Fungi, Dikarya, Ascomycota and Basidiomycota. IMA Fungus 2018, 9, 291–298. [Google Scholar] [CrossRef]
- Naranjo-Ortiz, M.A.; Gabaldón, T. Fungal evolution: Diversity, taxonomy and phylogeny of the Fungi. Biol. Rev. 2019, 94, 2101–2137. [Google Scholar] [CrossRef]
- Roetzer, A.; Gabaldón, T.; Schüller, C. From Saccharomyces cerevisiae to Candida glabrata in a few easy steps: Important adaptations for an opportunistic pathogen. FEMS Microbiol. Lett. 2011, 314, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Herrero, E. Evolutionary relationships between Saccharomyces cerevisiae and other fungal species as determined from genome comparisons. Rev Iberoam Micol. 2005, 22, 217–222. [Google Scholar] [CrossRef]
- Taylor, J.W. Evolutionary perspectives on human fungal pathogens. Cold Spring Harb. Perspect. Med. 2015, 5, a019588. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Loftus, B.J.; Fung, E.; Roncaglia, P.; Rowley, D.; Amedeo, P.; Bruno, D.; Vamathevan, J.; Miranda, M.; Anderson, I.J.; Fraser, J.A.; et al. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 2005, 307, 1321–1324. [Google Scholar] [CrossRef] [Green Version]
- Hedges, S.B.; Blair, J.E.; Venturi, M.L.; Shoe, J.L. A molecular timescale of eukaryote evolution and the rise of complex multicellular life. BMC Evol. Biol. 2004, 4, 2. [Google Scholar] [CrossRef] [Green Version]
- Karathia, H.; Vilaprinyo, E.; Sorribas, A.; Alves, R. Saccharomyces cerevisiae as a model organism: A comparative study. PLoS ONE 2011, 6, e1605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- dos Santos, S.C.; Teixeira, M.C.; Cabrito, T.R.; Sá-Correia, I. Yeast toxicogenomics: Genome-wide responses to chemical stresses with impact in environmental health, pharmacology, and biotechnology. Front. Genet. 2012, 3, 63. [Google Scholar] [CrossRef] [Green Version]
- Kell, D.B.; Dobson, P.D.; Oliver, S.G. Pharmaceutical drug transport: The issues and the implications that it is essentially carrier-mediated only. Drug Discov. Today 2011, 16, 704–714. [Google Scholar] [CrossRef]
- Liu, T.T.; Lee, R.E.B.; Barker, K.S.; Lee, R.E.; Wei, L.; Homayouni, R.; Rogers, P.D. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. Agents Chemother. 2005, 49, 2226–2236. [Google Scholar] [CrossRef] [Green Version]
- Jung, B.; Li, T.; Ji, S.; Lee, J. Efficacy of Diphenyleneiodonium Chloride (DPIC) Against Diverse Plant Pathogens. Mycobiology 2019, 47, 105. [Google Scholar] [CrossRef] [Green Version]
- Yang, J.; Gao, L.; Yu, P.; Kosgey, J.C.; Jia, L.; Fang, Y.; Xiong, J.; Zhang, F. In Vitro synergy of azole antifungals and methotrexate against Candida albicans. Life Sci. 2019, 235, 116827. [Google Scholar] [CrossRef] [PubMed]
- Steverding, D.; Evans, P.; Msika, L.; Riley, B.; Wallington, J.; Schelenz, S. In vitro antifungal activity of DNA topoisomerase inhibitors. Med. Mycol. 2012, 50, 333–336. [Google Scholar] [CrossRef] [Green Version]
- Routh, M.M.; Chauhan, N.M.; Karuppayil, S.M. Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans. Braz. J. Microbiol. 2013, 44, 855–859. [Google Scholar] [CrossRef] [Green Version]
- Siles, S.A.; Srinivasan, A.; Pierce, C.G.; Lopez-Ribot, J.L.; Ramasubramanian, A.K. High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob. Agents Chemother. 2013, 57, 3681–3687. [Google Scholar] [CrossRef] [Green Version]
- CDD/SPARCLE: The Conserved Domain Database in 2020—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/31777944/ (accessed on 3 August 2020).
- Chen, S.C.A.; Lewis, R.E.; Kontoyiannis, D.P. Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species. Virulence 2011, 2, 280. [Google Scholar] [CrossRef] [Green Version]
- Maltezou, H.C. Drug Resistance in Visceral Leishmaniasis. J. Biomed. Biotechnol. 2010. [Google Scholar] [CrossRef] [Green Version]
- Seifert, K.; Pérez-Victoria, F.J.; Stettler, M.; Sánchez-Cañete, M.P.; Castanys, S.; Gamarro, F.; Croft, S.L. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int. J. Antimicrob. Agents 2007, 30, 229–235. [Google Scholar] [CrossRef]
- Pierce, C.G.; Thomas, D.P.; Ló Pez-Ribot, J.L. Effect of tunicamycin on Candida albicans biofilm formation and maintenance. J. Antimicrob Chemother. 2009, 63, 473–479. [Google Scholar] [CrossRef] [Green Version]
- Omran, N.-Z.C.; Harun, H.-A.W. Synergism effect of tunicamycin and amphotericin B causes suppression to the MP65 and ERG3 gene in oral associated- Candida albicans and C. dubliniensis. Biotechnol. Biotechnol. Equip. 2016, 30, 1199–1206. [Google Scholar] [CrossRef] [Green Version]
- Edlind, T.D.; Henry, K.W.; Vermitsky, J.P.; Edlind, M.P.; Raj, S.; Katiyar, S.K. Promoter-dependent disruption of genes: Simple, rapid, and specific PCR-based method with application to three different yeast. Curr. Genet. 2005, 48, 117–125. [Google Scholar] [CrossRef]
- Vargas, R.C.; Tenreiro, S.; Teixeira, M.C.; Fernandes, A.R.; Sá-Correia, I. Saccharomyces cerevisiae multidrug transporter Qdr2p (YIL121WP): Localization and function as a quinidine resistance determinant. Antimicrob. Agents Chemother. 2004, 48, 2531–2537. [Google Scholar] [CrossRef] [Green Version]
- Tenreiro, S.; Vargas, R.C.; Teixeira, M.C.; Magnani, C.; Sá-Correia, I. The yeast multidrug transporter Qdr3 (YBR043C): Localization and role as a determinant of resistance to quinidine, barban, cisplatin, and bleomycin. Biochem. Biophys. Res. Commun. 2005, 327, 952–959. [Google Scholar] [CrossRef]
- Teixeira, M.C.; Cabrito, T.R.; Hanif, Z.M.; Vargas, R.C.; Tenreiro, S.; Sá-Correia, I. Yeast response and tolerance to polyamine toxicity involving the drug: H+ antiporter Qdr3 and the transcription factors Yap1 and Gcn4. Microbiology 2010, 157, 945–956. [Google Scholar] [CrossRef] [Green Version]
- Vargas, R.C.; García-Salcedo, R.; Tenreiro, S.; Teixeira, M.C.; Fernandes, A.R.; Ramos, J.; Sá-Correia, I. Saccharomyces cerevisiae multidrug resistance transporter Qdr2 is implicated in potassium uptake, providing a physiological advantage to quinidine-stressed cells. Eukaryot. Cell 2007, 6, 134–142. [Google Scholar] [CrossRef] [Green Version]
- Costa, C.; Pires, C.; Cabrito, T.R.; Renaudin, A.; Ohno, M.; Chibana, H.; Sá-Correia, I.; Teixeira, M.C. Candida glabrata drug:H+ antiporter CgQdr2 confers imidazole drug resistance, being activated by transcription factor CgPdr1. Antimicrob. Agents Chemother. 2013, 57, 3159–3167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Santos, R.; Cavalheiro, M.; Costa, C.; Takahashi-Nakaguchi, A.; Okamoto, M.; Chibana, H.; Teixeira, M.C. Screening the Drug:H+ Antiporter Family for a Role in Biofilm Formation in Candida glabrata. Front. Cell. Infect. Microbiol. 2020, 10, 29. [Google Scholar] [CrossRef] [Green Version]
- Shah, A.H.; Singh, A.; Dhamgaye, S.; Chauhan, N.; Vandeputte, P.; Suneetha, K.J.; Kaur, R.; Mukherjee, P.K.; Chandra, J.; Ghannoum, M.A.; et al. Novel role of a family of major facilitator transporters in biofilm development and virulence of Candida albicans. Biochem. J. 2014, 460, 223–235. [Google Scholar] [CrossRef] [Green Version]
- Gautam, P.; Shankar, J.; Madan, T.; Sirdeshmukh, R.; Sundaram, C.S.; Gade, W.N.; Basir, S.F.; Sarma, P.U. Proteomic and transcriptomic analysis of Aspergillus fumigatus on exposure to amphotericin B. Antimicrob. Agents Chemother. 2008, 52, 4220–4227. [Google Scholar] [CrossRef] [Green Version]
- Nourani, A.; Wesolowski-Louvel, M.; Delaveau, T.; Jacq, C.; Delahodde, A. Multiple-drug-resistance phenomenon in the yeast Saccharomyces cerevisiae: Involvement of two hexose transporters. Mol. Cell. Biol. 1997, 17, 5453–5460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dos Santos, S.C.; Tenreiro, S.; Palma, M.; Becker, J.; Sá-Correia, I. Transcriptomic profiling of the Saccharomyces cerevisiae response to quinine reveals a glucose limitation response attributable to drug-induced inhibition of glucose uptake. Antimicrob. Agents Chemother. 2009, 53, 5213–5223. [Google Scholar] [CrossRef] [Green Version]
- Munday, J.C.; Settimo, L.; de Koning, H.P. Transport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma brucei. Front. Pharmacol. 2015, 6, 32. [Google Scholar] [CrossRef]
- Verstrepen, K.J.; Fink, G.R. Genetic and Epigenetic Mechanisms Underlying Cell-Surface Variability in Protozoa and Fungi. Annu. Rev. Genet. 2009, 43, 1–24. [Google Scholar] [CrossRef]
- Sundar, S.; Chakravarty, J. An update on pharmacotherapy for leishmaniasis. Exp. Opin. Pharmacother. 2015, 16, 237–252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pérez-Victoria, F.J.; Sánchez-Cañete, M.P.; Seifert, K.; Croft, S.L.; Sundar, S.; Castanys, S.; Gamarro, F. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist. Updat. 2006, 9, 26–39. [Google Scholar] [CrossRef]
- De Castro Spadari, C.; Vila, T.; Rozental, S.; Ishida, K. Miltefosine has a postantifungal effect and induces apoptosis in Cryptococcus yeasts. Antimicrob. Agents Chemother. 2018, 62. [Google Scholar] [CrossRef] [Green Version]
- Vila, T.V.M.; Chaturvedi, A.K.; Rozental, S.; Lopez-Ribot, J.L. In vitro activity of miltefosine against Candida albicans under planktonic and biofilm growth conditions and in vivo efficacy in a murine model of oral candidiasis. Antimicrob. Agents Chemother. 2015, 59, 7611–7620. [Google Scholar] [CrossRef] [Green Version]
- Vila, T.; Ishida, K.; Seabra, S.H.; Rozental, S. Miltefosine inhibits Candida albicans and non-albicans Candida spp. biofilms and impairs the dispersion of infectious cells. Int. J. Antimicrob. Agents 2016, 48, 512–520. [Google Scholar] [CrossRef] [PubMed]
- Imbert, S.; Palous, M.; Meyer, I.; Dannaoui, E.; Mazier, D.; Datry, A.; Fekkar, A. In vitro combination of voriconazole and miltefosine against clinically relevant molds. Antimicrob. Agents Chemother. 2014, 58, 6996–6998. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Levine, N.D.; Corliss, J.O.; Cox, F.E.G.; Deroux, G.; Grain, J.; Honigberg, B.M.; Leedale, G.F.; Loeblich, A.R.; Lom, J.; Lynn, D.; et al. A Newly Revised Classification of the Protozoa. J. Protozool. 1980, 27, 37–58. [Google Scholar] [CrossRef]
- Alsford, S.; Eckert, S.; Baker, N.; Glover, L.; Sanchez-Flores, A.; Leung, K.F.; Turner, D.J.; Field, M.C.; Berriman, M.; Horn, D. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 2012, 482, 232–236. [Google Scholar] [CrossRef] [Green Version]
- Baker, N.; Alsford, S.; Horn, D. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol. Biochem. Parasitol. 2011, 176, 55–57. [Google Scholar] [CrossRef]
- Field, M.C.; Horn, D.; Fairlamb, A.H.; Ferguson, M.A.J.; Gray, D.W.; Read, K.D.; De Rycker, M.; Torrie, L.S.; Wyatt, P.G.; Wyllie, S.; et al. Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need. Nat. Rev. Microbiol. 2017, 15, 217–231. [Google Scholar] [CrossRef] [Green Version]
- McCarthy, J.S.; Wortmann, G.W.; Kirchhoff, L.V. Drugs for Protozoal Infections Other Than Malaria. In Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases; Elsevier Inc.: Amsterdam, The Netherlands, 2014; Volume 1, pp. 510–518. ISBN 9996096742. [Google Scholar]
- Mäser, P.; Sütterlin, C.; Kralli, A.; Kaminsky, R. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 1999, 285, 242–244. [Google Scholar] [CrossRef]
- Baker, N.; Glover, L.; Munday, J.C.; Andrés, D.A.; Barrett, M.P.; De Koning, H.P.; Horn, D. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc. Natl. Acad. Sci. USA 2012, 109, 10996–11001. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schmidt, R.S.; Macêdo, J.P.; Steinmann, M.E.; Salgado, A.G.; Bütikofer, P.; Sigel, E.; Rentsch, D.; Mäser, P. Transporters of Trypanosoma brucei—Phylogeny, physiology, pharmacology. FEBS J. 2018, 285, 1012–1023. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marsiccobetre, S.; Rodríguez-Acosta, A.; Lang, F.; Figarella, K.; Uzcátegui, N.L. Aquaglyceroporins Are the Entry Pathway of Boric Acid in Trypanosoma brucei. Biochim. Biophys. Acta Biomembr. 2017, 1859, 679–685. [Google Scholar] [CrossRef] [PubMed]
- Iavazzo, C.; Gkegkes, I.D.; Zarkada, I.M.; Falagas, M.E. Boric Acid for Recurrent Vulvovaginal Candidiasis: The Clinical Evidence. J. Women’s Health 2011, 20, 1245–1255. [Google Scholar] [CrossRef]
- Costa, C.; Ponte, A.; Pais, P.; Santos, R.; Cavalheiro, M.; Yaguchi, T.; Chibana, H.; Teixeira, M.C. New Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiae. PLoS ONE 2015, 10, e0135110. [Google Scholar] [CrossRef]
- Beese-Sims, S.E.; Pan, S.J.; Lee, J.; Hwang-Wong, E.; Cormack, B.P.; Levin, D.E. Mutants in the Candida glabrata glycerol channels are sensitized to cell wall stress. Eukaryot. Cell 2012, 11, 1512–1519. [Google Scholar] [CrossRef] [Green Version]
- Garcia-Salcedo, J.A.; Unciti-Broceta, J.D.; Valverde-Pozo, J.; Soriano, M. New approaches to overcome transport related drug resistance in trypanosomatid parasites. Front. Pharmacol. 2016, 7, 351. [Google Scholar] [CrossRef] [PubMed]
- Vincent, I.M.; Creek, D.; Watson, D.G.; Kamleh, M.A.; Woods, D.J.; Wong, P.E.; Burchmore, R.J.S.; Barrett, M.P. A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes. PLoS Pathog. 2010, 6, e1001204. [Google Scholar] [CrossRef] [Green Version]
- Durdu, M.; Ilkit, M.; Tamadon, Y.; Tolooe, A.; Rafati, H.; Seyedmousavi, S. Topical and systemic antifungals in dermatology practice. Expert Rev. Clin. Pharmacol. 2017, 10, 225–237. [Google Scholar] [CrossRef]
- Pais, P.; Galocha, M.; Teixeira, M.C. Genome-Wide Response to Drugs and Stress in the Pathogenic Yeast Candida glabrata. Prog. Mol. Subcell. Biol. 2019, 58, 155–193. [Google Scholar]
- Campoy, S.; Adrio, J.L. Antifungals. Biochem. Pharmacol. 2017, 133, 86–96. [Google Scholar] [CrossRef]
- Noël, T.; François, F.; Paumard, P.; Chastin, C.; Brèthes, D.; Villard, J. Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: Indirect evidence of a fluconazole uptake transporter. Antimicrob. Agents Chemother. 2003, 47, 1275–1284. [Google Scholar] [CrossRef] [Green Version]
- Ostrosky-Zeichner, L.; Casadevall, A.; Galgiani, J.N.; Odds, F.C.; Rex, J.H. An insight into the antifungal pipeline: Selected new molecules and beyond. Nat. Rev. Drug Discov. 2010, 9, 719–727. [Google Scholar] [CrossRef]
- Mesa-Arango, A.C.; Scorzoni, L.; Zaragoza, O. It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. Front. Microbiol. 2012, 3, 286. [Google Scholar] [CrossRef] [Green Version]
- Shapiro, R.S.; Robbins, N.; Cowen, L.E. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 2011, 75, 213–267. [Google Scholar] [CrossRef] [Green Version]
- Denning, D.W. Echinocandin antifungal drugs. Lancet 2003, 362, 1142–1151. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Galocha, M.; Costa, I.V.; Teixeira, M.C. Carrier-Mediated Drug Uptake in Fungal Pathogens. Genes 2020, 11, 1324. https://doi.org/10.3390/genes11111324
Galocha M, Costa IV, Teixeira MC. Carrier-Mediated Drug Uptake in Fungal Pathogens. Genes. 2020; 11(11):1324. https://doi.org/10.3390/genes11111324
Chicago/Turabian StyleGalocha, Mónica, Inês Vieira Costa, and Miguel Cacho Teixeira. 2020. "Carrier-Mediated Drug Uptake in Fungal Pathogens" Genes 11, no. 11: 1324. https://doi.org/10.3390/genes11111324